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BACKGROUND: Use of immunosuppressive drugs post organ transplantation, and prolonged use of glucorticoids for other conditions
have been associated with subsequent risk of certain malignancies, that is, skin cancers and lymphoma. There is evidence that the
incidence of bladder cancer is also elevated among organ transplant recipients, however, it is unknown whether other groups of
patients, that is, those taking oral glucocorticoids, likewise are at an increased risk.
METHODS: In a population-based case–control study in New Hampshire, USA, we compared the use of glucocorticoids in 786 bladder
cancer cases and in 1083 controls. We used unconditional logistic regression analysis to compute adjusted odds ratios (ORs)
associated with oral glucocorticoid use.
RESULTS: In our analysis, the risk of bladder cancer was related to a history of prolonged oral glucocorticoid use (OR¼1.85, 95%
CI¼1.24–2.76, adjusted for age, gender and smoking). Associations with oral glucocorticoid use were stronger for invasive tumours
(OR¼2.12, 95% CI¼1.17–3.85) and tumours with high (3þ) p53 staining intensity (OR¼2.35, 95% CI¼1.26–4.36).
CONCLUSION: Our results raise the possibility of an increased risk of bladder cancer from systemic use of glucocorticoids, and a
potential role of immune surveillance in bladder cancer aetiology.
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With an estimated 68810 new cases in 2008, bladder cancer is the
fifth most commonly diagnosed cancer in the United States of
America (Scosyrev et al, 2009). Several risk factors have been
identified as potential causes of bladder cancer, including tobacco
use, occupational exposure to aromatic amines and polycyclic
aromatic hydrocarbons (Johansson and Cohen, 1997; Silverman
et al, 2006), and treatment with cyclophosphamide (Kinlen,
1985; Baker et al, 1987; Radis et al, 1995; Volkmer et al, 2005).
Glucocorticoids, often in combination with other immuno-
suppressive drugs, are a part of post-transplant therapy and alone
are used to treat other acute or chronic inflammatory conditions,
including rheumatoid arthritis, inflammatory bowel disease and
asthma (Zoorob and Cender, 1998). There is evidence of an
enhanced risk of certain types of cancer, including skin cancers
and lymphomas, among organ transplant recipients (Birkeland
et al, 1995, 2000; Kyllonen et al, 2000; Adami et al, 2003; Vajdic
et al, 2006) and prolonged users of immunosuppressive drugs,
such as glucorticoids, for other conditions (Karagas et al, 2001;
Sorensen et al, 2004; Jensen et al, 2009). The incidence of bladder
cancer is two- to four-fold higher among organ transplant
recipients (Buzzeo et al, 1997); however, the risk among patients
using oral glucocorticoids for other reasons is unknown. There-
fore, we examined the potential risk of bladder cancer associated
with glucocorticoid use in non-transplant recipients as part of an
ongoing population-based case–control study of bladder cancer
conducted in New Hampshire, USA.
MATERIALS AND METHODS
Study group
Through the New Hampshire State Department of Health and
Human Services’ rapid reporting Cancer Registry, we identified
newly diagnosed cases of bladder cancer among New Hampshire
residents, aged 25–74 during the 1 July 1994 to 31 December 2001
period. For efficiency, we shared controls with a study of non-
melanoma skin cancer covering a diagnostic period of 1 July 1993
to 30 March 2000, along with additional controls frequency
matched to the bladder cancer cases by age and gender (Wallace
et al, 2009). Controls o65 years of age were selected using
population lists obtained from the New Hampshire Department of
Transportation. Controls 65 years of age and older were chosen
from data files provided by the Centers for Medicare & Medicaid
Services (CMS) of New Hampshire, as described previously
(Fortuny et al, 2007).
Interviews
We conducted standardized personal interviews with the study
participants to obtain information on demographic traits, use of
tobacco (including frequency, duration and intensity of cigarette
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ssmoking), alcohol and other exposures. We requested the original
paraffin-embedded tumour specimen for histopathology re-review
by the study pathologist who classified tumours according to WHO
1973 and WHO ISUP criteria (Schned et al, 2007). Owing to the
high concordance rates for overall diagnosis (490%), we classified
subjects based on the original pathologist’s diagnosis; whereas
tumour morphology, extent of disease and grade were based
solely on the standardized histopathology re-review by the study
pathologist. Immunohistochemical analysis of the tumours was
carried out for TP53 using a monoclonal antibody (BioGenex,
San Ramon, CA, USA), and scored for intensity and the percentage
of tumour cells staining positively as markers of tumour severity,
as the number of tumours having TP53 mutations increases with
the degree of invasiveness of the tumour (Kelsey et al, 2004) and
may represent an aetiologically distinct subgroup of tumours
(Kelsey et al, 2005; Wallace et al, 2009). We obtained informed
consent from each participant and all procedures and study
materials were approved by the Committee for the Protection of
Human Subjects at Dartmouth College.
Drug use assessment
Participants were asked if their doctor had ever prescribed
glucocorticoids or steroids as pills, injections or inhalers for
1 month or longer before their reference date (defined as the
diagnosis date of the cases and a comparable date randomly
assigned to the controls). Those who responded positively were
considered users and were asked the age they were first treated, the
condition for which the glucocorticoids were prescribed, the name
of the drug, dose and duration of the treatment. Those who
responded that they did not use glucocorticoids for at least
1 month were considered non-users. To aid recall, we developed
a list of glucocorticoids and other immunosuppressive drugs
(trade name, generic name and description) and a pictorial guide
showing the most commonly used drugs grouped by pill colour,
size and shape. To minimize potential reporting bias, we did not
reveal the specific hypotheses-of-interest to either the interviewer
or participant, and we did not inform the interviewers of the
case–control status of participants.
Statistical analysis
We computed odds ratios (ORs) and their 95% confidence
intervals (CIs) for bladder cancer associated with the use of
glucocorticoids before the reference date using unconditional
logistic regression, taking into account multiple confounding
factors (Breslow and Day, 1980). In addition to age and sex, we also
adjusted for the potential confounding effects of smoking status
(current, former and never). Further, we assessed the possibility
that education, as a marker of socioeconomic status, could act as a
potential confounder, but the inclusion of this variable did not
significantly influence our results, and therefore was not included
in the final models.
We conducted a combined analysis of all bladder cancers, as
well as specifically on pathologically confirmed transitional cell
carcinomas. In addition, we carried out a case-only analysis
comparing glucocorticoid users to non-users according to
subgroups defined by the extent of disease (low grade non-
invasive, high grade non-invasive, invasive or carcinoma in situ)
and TP53 staining intensity (o3o r3 þ) to examine whether
glucocorticoid use was associated with tumour aggressiveness.
RESULTS
A total of 824 cases took part in the study (85% response rate of
those eligible), and from 786 (95%) we obtained data on the use of
oral glucocorticoids. A total of 1119 controls took part in the study
(70% of those eligible), and from 1083 (97%) we obtained data on
the use of oral glucocorticoids (Table 1). Cases were more likely
male than were controls, but did not differ by age. A higher
percentage of cases than controls were current smokers, who
reported a family history of bladder cancer and did not have
education beyond high school or technical college (Table 1).
Overall, 5% of controls and 8% of cases reported a history of
oral glucocorticoid use for 1 month or longer. Prednisone
accounted for 87% of the reported oral glucocorticoid use. Of
the histologically reviewed cancers, 98% were transitional cell
(urothelial) carcinomas (TCC), 61% were non-invasive low grade,
8% were non-invasive high grade, 27% were invasive and 4% were
in situ carcinomas (Table 1).
Associations with glucocorticoid use
Any glucocorticoid use was associated with an increased risk of
bladder cancer, and the association was stronger for oral use
(OR¼1.85, 95% CI¼1.24–2.76) than inhaled use (Table 2).
Although there was not a clear trend in risk by categories of
duration of use, the OR was highest among those who used oral
glucocorticoids for 5 years or longer (OR¼3.39, 95% CI¼0.98–




n¼1083 (%) n¼786 (%)
Age (years)
o55 263 (24) 155 (20)
55–63 259 (24) 210 (27)
64–68 235 (22) 172 (22)
X69 326 (30) 249 (32)
Gender
Male 667 (61) 597 (76)
Female 416 (39) 189 (24)
Smoking
Never 365 (33) 142 (18)
Former 538 (50) 388 (49)
Current 180 (17) 256 (33)
Pack-years
p32 412 (60) 249 (39)
432 275 (40) 386 (61)
Education
High school or technical college 498 (47) 560 (72)
College 364 (33) 171 (22)
Graduate or professional school 216 (20) 48 (6)
Family history of bladder cancer
No 1033 (99) 679 (95)
Yes 14 (1) 37 (5)
Histology
c
Transitional — — 676 (98)
Non-transitional — — 12 (2)
Stage
Non-invasive; low grade — — 417 (63)
Non-invasive; high grade — — 52 (8)
Invasive — — 190 (29)
Carcinoma in situ — — 29 (4)
aFive controls missing data on education and 36 missing data on family history.
bSeven
cases missing data on education, 70 missing data on family history, 98 missing data on
transitional cell status and 98 missing data on bladder cancer stage.
cNon-transitional
cell carcinomas include 2 spindle cell carcinoma, 3 small cell carcinoma, 1 squamous
cell carcinoma in situ, 4 squamous cell carcinomas and 2 adenocarcinoma.
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s11.74) (Table 2). Data on dose was available on 63 (65%) of the 97
individuals who reported prednisone use. Examining maximum
daily reported dose, we detected an elevated OR primarily in the
strata of X50mg (OR¼4.12, 95% CI¼1.12–15.15), but not for
o10mg (OR¼0.76, 95% CI¼0.25–2.34) or for 10–49mg
(OR¼1.07, 95% CI¼0.43–2.70). Stratifying by reasons for use
led to small strata, but did not suggest confounding by indication
(Table 2). ORs appeared higher among never smokers (OR¼5.24,
95% CI¼2.20–12.50) than smokers (OR¼1.42, 95% CI¼0.91–
2.21) (P for interaction¼0.004); however, ORs were elevated in
both groups and there were few never smokers.
Subgroups by tumour characteristics
Restriction to transitional cell carcinomas did not affect our
risk estimate for oral glucocorticoid use (TCC OR¼1.85, 95%
CI¼1.22–2.81). Further, using a case–case approach, we found
higher ORs associated with more advanced disease stage and grade
(Table 3). Oral glucocorticoid users had somewhat higher odds of
having TP53 high-intensity stained tumours than TP53 negative
tumours.
DISCUSSION
Immunosuppressive therapy, usually a combination of cytotoxic
drugs and glucocorticoids, is commonly prescribed to organ
transplant recipients, in order to prevent allograft rejection. Gluco-
corticoids, alone or in combination with other immunosuppressive
drugs, are used to help treat many chronic inflammatory
conditions, such as rheumatoid arthritis and asthma. Long-term
immunosuppressive therapy has been shown to increase the risk of
many types of malignancies among organ transplant recipients
(Birkeland et al, 1995, 2000; Kyllonen et al, 2000; Adami et al, 2003;
Vajdic et al, 2006). Further, previous research has found increased
risk of skin cancers and non-Hodgkin’s lymphoma among long-
term glucocorticoid users (Karagas et al, 2001; Sorensen et al,
2004; Jensen et al, 2009). Our findings suggest that long-term
glucocorticoid users may have an increased risk of bladder cancer,
although to a lesser extent than organ transplant recipients.
Previous large cohort studies have found risk of bladder cancer in
transplant recipients to be elevated two- to five-fold over the general
population, a smaller effect size than seen with skin cancer or
lymphoma (Kyllonen et al, 1994; Buzzeo et al, 1997; Adami et al,
2003). Bladder cancer is a far less common disease than skin cancer,
and thus it is not surprising that cohort studies would observe few if
any cases (Master et al, 2004; Kamal et al, 2007). An exception was a
Taiwanese study that reported bladder cancer as the most common
type of post-transplant malignancy with an incidence of 4.1%
among kidney transplant recipients (Wu et al,2 0 0 4 ) .
In non-transplant cohorts, cyclophosphamide and other drugs
with immunosuppressive effects also have been linked to increased
risk of bladder cancer. Several previous studies have found that
cyclophosphamide therapy in patients with Wegener’s granulo-
matosis is associated with an increased risk of bladder cancer
(Travis et al, 1995; Talar-Williams et al, 1996; Knight et al, 2004).
Patients with rheumatoid arthritis treated with long-term cyclo-
phosphamide (Radis et al, 1995) and patients on cyclophos-
phamide or azathioprine for underlying autoimmune disorders
(e.g., rheumatoid arthritis, Crohn’s disease) had reported increa-
sed risks of bladder cancer (Kinlen, 1985). In another study,
patients with rheumatic disease on multiple drugs, including
azathioprine, methotrexate, cyclophosphamide and chlorambucil
were found to have an enhanced risk of neoplasms, including in
the bladder (Asten et al, 1999). In a more recent cohort study,
rheumatoid arthritis patients on either methotrexate or tumour
necrosis factor alpha (TNF-a) inhibitors, were twice as likely
to develop bladder cancer as the general population (Setoguchi
et al, 2006).
An enhanced risk of bladder cancer also has been observed
in other immunosuppressed populations, including HIV-infected
and AIDS patients. Manfredi et al (2006), published a case series
Table 2 Adjusted odds ratios (ORs) and confidence intervals (CIs) for
oral glucocorticoid use among cases and controls
Controls







No use 1032 725 1.00 (reference)
Both oral and inhaled 9 11 2.17 (0.87–5.42)
Oral only 42 50 1.78 (1.15–2.76)
Inhaled only 32 38 1.52 (0.92–2.51)
Oral glucocorticoid use
d
No 1032 725 1.00 (reference)
Yes 51 61 1.85 (1.24–2.76)
Former 33 35 1.50 (0.91–2.48)
Current 17 21 2.18 (1.11–4.28)
Total duration of oral glucocorticoid use
d
No use 1032 725 1.00 (reference)
p2 years 38 46 1.87 (1.18–2.96)
2–5 years 8 7 1.29 (0.50–3.64)
45 years 4 8 3.39 (0.98–11.74)
Reason for oral glucocorticoid use
e
No use 1032 725 1.00 (reference)
Respiratory conditions
and asthma
15 16 1.73 (0.83–3.60)
Musculoskeletal and
connective tissue disease
20 21 1.40 (0.74–2.68)
Neoplasm 1 4 3.51 (0.39–31.90)
Allergy 3 9 7.39 (1.93–28.29)
Gastrointestinal disease 5 5 2.10 (0.57–7.66)
Other 10 3 0.46 (0.12–1.70)
aOne control missing data on current/former oral glucocorticoid status and one
control missing data on duration of oral glucocorticoid use.
bFive cases missing data
on current/former oral glucocorticoid status.
cModel adjusted for age, sex and
smoking status.
dExcludes 70 patients who took only inhaled steroids.
eExcludes 90
patients with any inhaled steroid use; reason for use may include multiple conditions
or no conditions for each individual.
Table 3 Adjusted odds ratios (ORs) (95% confidence interval (CI)) for
pathologically confirmed transitional cell (urothelial) carcinomas among





n % n % Adjusted OR
b (95% CI)
Disease stage
Non-invasive; low grade 387 61% 30 56% 1.66 (1.03–2.70)
Non-invasive; high grade 48 8% 4 7% 2.03 (0.68–6.06)
Invasive 173 27% 17 31% 2.12 (1.17–3.85)
Carcinoma in situ 26 4% 3 6% 3.55 (0.98–12.85)
p53 Staining intensity
c
o3 440 73% 37 70% 1.79 (1.13–2.82)
3+ 159 27% 16 30% 2.35 (1.26–4.36)
aExcludes 38 cases who reported taking only inhaled steroids.
bModel adjusted for
age, sex and smoking status.
c36 individuals missing data on p53 staining intensity.
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sand literature review with thirteen reports of HIV-infected patients
with bladder carcinoma. Although the prevalence of bladder
cancer is less than Kaposi’s sarcoma, lymphoma and cervical
cancer, this report is consistent with our observations and
suggests the necessity of further research addressing the associa-
tion of bladder cancer with immunosuppression. Further in recent
work, Roberts et al (2008) found evidences of polyoma virus
in urothelial carcinomas of renal transplant patients, suggesting
a potential aetiological role of polyoma virus in post-transplant
bladder malignancies. However, they acknowledge that it is
possible that tumour cells are more susceptible to BK virus
infection than normal cells, and thus that the infection is a
consequence rather than a cause. Still this hypothesis may warrant
further investigation.
It is conceivable that our findings were because of chance,
unmeasured confounding or other biases. Differential misclassifi-
cation due to recall bias is possible, although we attempted to
minimize this through the use of a pictorial guide of common
medications. Moreover, it seems unlikely that bladder cancer
patients would recognize oral glucocorticoids as a possible
aetiological factor. Another advantage of our study was that both
cases and controls were drawn from the general population; among
cases, over 95% reported having a valid driver’s license (those o65
years) or being enrolled in Medicare (those 65 years and older),
ensuring our control group was represented within our case group.
Our study population was relatively large, although the statistical
power diminished in certain categories (i.e., by duration of use).
We assessed the potential confounding effects of multiple factors
and confounding by indication was unlikely, as we did not find
systematic differences in the ORs for oral glucocorticoid use by
reason for use. A weaker association observed with inhaled
steroids is plausible because of the minimal systemic effects of
inhaled steroids (Hardman et al, 1996; Zoorob and Cender, 1998).
Oral glucocorticoid users appeared to be at an enhanced risk
of specifically developing invasive, TP53 positive (3þ staining
intensity) bladder cancer compared with non-users. This is
supported by previous research that has observed more rapid
progression of transitional cell carcinomas in immunosuppressed
patients (Wang et al, 2002). This is perhaps because tumours are
able to progress more quickly with diminished immunosurveil-
lance. Nonetheless, our findings will need to be confirmed or
refuted in future studies. If an enhanced risk of bladder cancer,
particularly advanced disease is confirmed, it might indicate the
need for closer monitoring of individuals who regularly take
glucocorticoids.
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